Western Institutional Review Board Receives ISO Certification
WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced today that its Western Institutional Review Board® company has been certified to ISO 9001:2008 by BSI.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, announced that its Western Institutional Review Board® (WIRB®) company has been certified to ISO 9001:2008, which means that it operates an excellent quality management system.
All ISO 9000 standards are based on a series of quality management principles. They require company leaders to establish clear goals and objectives for their quality management system and endeavor to get all their employees involved. Participating companies adopt a strong customer focus with employees aiming not just to meet customer expectations but to exceed them. They also take both a process- and systems-based management approach, and strive for continual improvement in their company’s overall performance, using internal audits to track progress. ISO 9001:2008 is implemented by more than one million companies and organizations in more than 170 countries, according to ISO.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
